NasdaqGS - Nasdaq Real Time Price ? USD Aclaris Therapeutics, Inc. (ACRS) Follow Compare 2.0500 -0.1300 (-5.96%) At close: November 15 at 4:00 PM EST 2.0500 0.00 (0.00%) After hours: November 15 at 5:13 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders will have a reason to smile today, with the analysts making... Simply Wall St. ? 5 days ago ACRS -5.96% Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates The analysts might have been a bit too bullish on Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ), given that the company... Simply Wall St. ? 8 days ago ACRS -5.96% Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates Aclaris (ACRS) delivered earnings and revenue surprises of -37.50% and 47.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 11 days ago ACRS -5.96% Aclaris: Q3 Earnings Snapshot WAYNE, Pa. AP) — Aclaris Therapeutics Inc. ACRS) on Wednesday reported a loss of $7.6 million in its third quarter. Associated Press Finance ? 11 days ago ACRS -5.96% Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update – First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. "The third quarter of 2024 marked an importan GlobeNewswire ? 11 days ago ACRS -5.96% Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap As major U.S. indexes recently experienced a downturn, with technology stocks leading the decline and Treasury yields reaching a three-month high, investors are increasingly seeking opportunities beyond the usual large-cap stocks. Penny stocks, while an older term, continue to represent smaller or newer companies that may offer both affordability and growth potential for those willing to explore them. In this article, we examine three penny stocks that stand out for their financial strength... Simply Wall St. ? 25 days ago GDTC ACRS -5.96% Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc On September 30, 2024, Millennium Management LLC, a prominent hedge fund, executed a significant transaction involving the shares of Aclaris Therapeutics Inc (NASDAQ:ACRS). The firm reduced its holdings by 331,252 shares, resulting in a new total of 3,005,598 shares in the biopharmaceutical company. This move reflects a strategic adjustment in Millenniums investment portfolio, with the shares priced at $1.15 during the transaction. GuruFocus.com ? last month ACRS -5.96% Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? Here is how BellRing Brands (BRBR) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year. Zacks ? last month BRBR ACRS -5.96% Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial Topline data from this trial is anticipated in the first half of next year. Clinical Trials Arena ? last month ACRS -5.96% Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris' Phase 2a clinical trial of ATI-2138, an investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase (JAK) 3, for the treatment of moderate to severe atopic dermatitis (AD). "We ar GlobeNewswire ? last month ACRS -5.96% Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York. A webcast of the fireside chat may be accessed through the “Events” page GlobeNewswire ? 2 months ago ACRS -5.96% Aclaris Therapeutics Second Quarter 2024 Earnings: Beats Expectations Aclaris Therapeutics ( NASDAQ:ACRS ) Second Quarter 2024 Results Key Financial Results Revenue: US$2.77m (up 48% from... Simply Wall St. ? 3 months ago ACRS -5.96% Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates Aclaris (ACRS) delivered earnings and revenue surprises of 21.05% and 58.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 3 months ago ACRS -5.96% Aclaris: Q2 Earnings Snapshot WAYNE, Pa. AP) — Aclaris Therapeutics Inc. ACRS) on Wednesday reported a loss of $11 million in its second quarter. Associated Press Finance ? 3 months ago ACRS -5.96% Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update -Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT? Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2024 and provided a corporate update. "With stu GlobeNewswire ? 3 months ago ACRS -5.96% Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely? There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... Simply Wall St. ? 3 months ago ACRS -5.96% Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? Here is how Aclaris Therapeutics (ACRS) and Adma Biologics (ADMA) have performed compared to their sector so far this year. Zacks ? 3 months ago ACRS -5.96% ADMA Aclaris Therapeutics Announces Sale of OLUMIANT? Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -- $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris’ future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales GlobeNewswire ? 4 months ago ACRS -5.96% Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year? Here is how Adma Biologics (ADMA) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year. Zacks ? 4 months ago ADMA ACRS -5.96% Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida. A webcast of the fireside chat may be accessed through GlobeNewswire ? 5 months ago ACRS -5.96% Performance Overview Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ACRS S&P 500 YTD +95.24% +23.08% 1-Year +201.47% +30.58% 3-Year -86.25% +25.36%
